Cosmos Health Enters Manufacturing Agreement with Libytec for PathMuscle
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Should l Buy COSM?
Cosmos Health 's wholly owned subsidiary, Cana Laboratories, has entered into a manufacturing and supply agreement to undertake the full end-to-end production of the pharmaceutical product PathMuscle for Libytec Pharmaceutical. Under the terms of the agreement, Cosmos Health will be responsible for the complete manufacturing of the finished pharmaceutical product, including formulation, production, quality control, and product release, in accordance with applicable regulatory requirements. The product will be distributed and commercially promoted in the Greek market by Libytec Pharmaceutical S.A., with the agreement providing for firm minimum committed production volumes of 591,500 units and expected cumulative production volumes over a five-year period anticipated to exceed 1.2 million units, subject to market demand and commercial performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COSM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COSM
About COSM
Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cosmos Health Expands Retail Footprint in the UK
- Market Expansion: Cosmos Health's antimicrobial skin cleanser, C-Scrub, is now available at Superdrug, the UK's second-largest beauty and health retailer, marking a significant expansion in the UK market that is expected to enhance brand visibility and market share.
- Retail Network Advantage: With over 830 stores across the UK and Ireland, including more than 200 pharmacies, Superdrug's listing of C-Scrub will significantly enhance its influence in the health and personal care sectors, further solidifying Cosmos Health's market position.
- Product Features: C-Scrub is a powerful antiseptic wash designed to reduce bacteria and help prevent infections, supporting effective skin hygiene and aligning with the growing consumer demand for health-focused products.
- Strategic Significance: CEO Greg Siokas stated that entering Superdrug reinforces the retail momentum for C-Scrub in the UK, strengthening the company's market positioning across diverse retail platforms and supporting the long-term development of its broader product portfolio.
See More
Cosmos Health Expands UK Retail Footprint with Tesco Partnership
- Retail Channel Expansion: Cosmos Health's antimicrobial skin cleanser, C-Scrub, is now available at Tesco, the UK's largest retailer with over $80 billion in annual revenue and nearly 30% market share, significantly enhancing C-Scrub's visibility and accessibility.
- Market Leadership: The partnership with Tesco not only boosts Cosmos Health's credibility in the UK market but also establishes a solid foundation for the potential rollout of additional products, further solidifying its position in European markets.
- Product Advantages: C-Scrub, designed to reduce bacteria and help prevent infection, supports effective skin hygiene and is expected to meet the growing demand for efficient cleaning products among UK consumers.
- Strategic Growth Opportunity: CEO Greg Siokas stated that this collaboration with Tesco represents a pivotal moment for Cosmos Health, providing not only growth opportunities for C-Scrub but also a powerful platform for future product launches, demonstrating the company's commitment to global market expansion.
See More
Cosmos Health Showcases at World Health Expo Dubai 2026
- Expo Participation: Cosmos Health participated in the World Health Expo Dubai from February 9-12, 2026, attracting over 235,000 visitors and 4,300 exhibitors, showcasing its influence in the global healthcare sector.
- Brand Promotion: The company highlighted its flagship product, Sky Premium Life®, which has strengthened its presence in Europe and the Middle East through expanded distribution agreements and new product launches, expected to drive future sales growth.
- Strategic Partnerships: During the expo, CEO Greg Siokas held productive meetings with potential commercial partners from new regions including Japan, China, and Latin America, aiming to strengthen strategic relationships and advance several potential agreements.
- Global Expansion: Cosmos Health successfully entered the North American market through its U.S. manufacturing capabilities and plans to further expand its global distribution network to support long-term brand development and value creation.
See More
Cosmos Health Expands Digital Asset Investment Strategy
- Digital Asset Expansion: Cosmos Health Inc. announced a $500,000 purchase of Bitcoin, marking an expansion of its digital assets program aimed at enhancing flexibility and diversification in capital deployment.
- Strategic Evolution: While Ethereum remains a cornerstone of the program, the addition of Bitcoin reflects the company's adaptability to market dynamics, expected to enhance its competitiveness in the digital asset space.
- Total Investment: To date, Cosmos Health has invested a total of $2.5 million in cryptocurrencies, demonstrating its ongoing commitment and strategic positioning in the digital asset arena.
- CEO Insights: CEO Greg Siokas stated that the investment in Bitcoin, executed at an average price below $70,000, reflects the potential for value creation by deploying capital during market downturns, further solidifying its overall capital deployment strategy.
See More
YYAI Director Hongyu Zhou Acquires 4.215M Shares at $1.37, Totaling $5.77M
- YYAI Large Transaction: Director Hongyu Zhou purchased 4.215 million shares of YYAI on Wednesday at $1.37 each, totaling an investment of $5.77 million, reflecting confidence in the company's future and contributing to a 15% increase in stock price on Friday.
- Investment History: Over the past twelve months, Zhou has made three purchases of YYAI shares, totaling $1.86 million at an average cost of $1.29 per share, indicating a sustained positive outlook on the company.
- Cosmos Health Insider Trading: CEO Grigorios Siokas bought 353,321 shares of COSM on Tuesday at $0.50 each, totaling $175,000, which reflects recognition of the company's value, even as the stock rose only 0.7% on Friday.
- Siokas' Investment History: Siokas has made 26 purchases of COSM shares over the past year, totaling $1.93 million at an average cost of $0.45 per share, demonstrating confidence in the company's long-term growth potential.
See More
Cosmos Health Inc. (COSM) Receives Zacks Coverage with $4.50 Price Target
- Coverage Initiation: Zacks Small-Cap Research initiated coverage on Cosmos Health on January 13, 2026, assigning a $4.50 per share valuation, reflecting the company's diversified revenue base and improving financial performance.
- Revenue Growth Outlook: Zacks projects Cosmos Health's revenues to grow from approximately $64.4 million in 2025 to $98.6 million in 2026, with expectations of exceeding $130 million by 2027, driven by higher-margin pharmaceuticals and nutraceuticals.
- U.S. Market Expansion: The report highlights Cosmos Health's entry into the U.S. market through the acquisition of ZipDoctor, a telehealth platform, and the launch of Sky Premium Life in the U.S. nutraceutical market, enhancing its competitive position.
- Advancing R&D Pipeline: Zacks notes Cosmos Health's ongoing development programs targeting obesity and multiple sclerosis, reflecting the company's strategic focus on addressing large disease markets and driving innovation in drug repurposing.
See More
Cosmos Health Expands Retail Footprint in the UK
- Market Expansion: Cosmos Health's antimicrobial skin cleanser, C-Scrub, is now available at Superdrug, the UK's second-largest beauty and health retailer, marking a significant expansion in the UK market that is expected to enhance brand visibility and market share.
- Retail Network Advantage: With over 830 stores across the UK and Ireland, including more than 200 pharmacies, Superdrug's listing of C-Scrub will significantly enhance its influence in the health and personal care sectors, further solidifying Cosmos Health's market position.
- Product Features: C-Scrub is a powerful antiseptic wash designed to reduce bacteria and help prevent infections, supporting effective skin hygiene and aligning with the growing consumer demand for health-focused products.
- Strategic Significance: CEO Greg Siokas stated that entering Superdrug reinforces the retail momentum for C-Scrub in the UK, strengthening the company's market positioning across diverse retail platforms and supporting the long-term development of its broader product portfolio.
See More
Cosmos Health Expands UK Retail Footprint with Tesco Partnership
- Retail Channel Expansion: Cosmos Health's antimicrobial skin cleanser, C-Scrub, is now available at Tesco, the UK's largest retailer with over $80 billion in annual revenue and nearly 30% market share, significantly enhancing C-Scrub's visibility and accessibility.
- Market Leadership: The partnership with Tesco not only boosts Cosmos Health's credibility in the UK market but also establishes a solid foundation for the potential rollout of additional products, further solidifying its position in European markets.
- Product Advantages: C-Scrub, designed to reduce bacteria and help prevent infection, supports effective skin hygiene and is expected to meet the growing demand for efficient cleaning products among UK consumers.
- Strategic Growth Opportunity: CEO Greg Siokas stated that this collaboration with Tesco represents a pivotal moment for Cosmos Health, providing not only growth opportunities for C-Scrub but also a powerful platform for future product launches, demonstrating the company's commitment to global market expansion.
See More
Cosmos Health Showcases at World Health Expo Dubai 2026
- Expo Participation: Cosmos Health participated in the World Health Expo Dubai from February 9-12, 2026, attracting over 235,000 visitors and 4,300 exhibitors, showcasing its influence in the global healthcare sector.
- Brand Promotion: The company highlighted its flagship product, Sky Premium Life®, which has strengthened its presence in Europe and the Middle East through expanded distribution agreements and new product launches, expected to drive future sales growth.
- Strategic Partnerships: During the expo, CEO Greg Siokas held productive meetings with potential commercial partners from new regions including Japan, China, and Latin America, aiming to strengthen strategic relationships and advance several potential agreements.
- Global Expansion: Cosmos Health successfully entered the North American market through its U.S. manufacturing capabilities and plans to further expand its global distribution network to support long-term brand development and value creation.
See More
Cosmos Health Expands Digital Asset Investment Strategy
- Digital Asset Expansion: Cosmos Health Inc. announced a $500,000 purchase of Bitcoin, marking an expansion of its digital assets program aimed at enhancing flexibility and diversification in capital deployment.
- Strategic Evolution: While Ethereum remains a cornerstone of the program, the addition of Bitcoin reflects the company's adaptability to market dynamics, expected to enhance its competitiveness in the digital asset space.
- Total Investment: To date, Cosmos Health has invested a total of $2.5 million in cryptocurrencies, demonstrating its ongoing commitment and strategic positioning in the digital asset arena.
- CEO Insights: CEO Greg Siokas stated that the investment in Bitcoin, executed at an average price below $70,000, reflects the potential for value creation by deploying capital during market downturns, further solidifying its overall capital deployment strategy.
See More
YYAI Director Hongyu Zhou Acquires 4.215M Shares at $1.37, Totaling $5.77M
- YYAI Large Transaction: Director Hongyu Zhou purchased 4.215 million shares of YYAI on Wednesday at $1.37 each, totaling an investment of $5.77 million, reflecting confidence in the company's future and contributing to a 15% increase in stock price on Friday.
- Investment History: Over the past twelve months, Zhou has made three purchases of YYAI shares, totaling $1.86 million at an average cost of $1.29 per share, indicating a sustained positive outlook on the company.
- Cosmos Health Insider Trading: CEO Grigorios Siokas bought 353,321 shares of COSM on Tuesday at $0.50 each, totaling $175,000, which reflects recognition of the company's value, even as the stock rose only 0.7% on Friday.
- Siokas' Investment History: Siokas has made 26 purchases of COSM shares over the past year, totaling $1.93 million at an average cost of $0.45 per share, demonstrating confidence in the company's long-term growth potential.
See More
Cosmos Health Inc. (COSM) Receives Zacks Coverage with $4.50 Price Target
- Coverage Initiation: Zacks Small-Cap Research initiated coverage on Cosmos Health on January 13, 2026, assigning a $4.50 per share valuation, reflecting the company's diversified revenue base and improving financial performance.
- Revenue Growth Outlook: Zacks projects Cosmos Health's revenues to grow from approximately $64.4 million in 2025 to $98.6 million in 2026, with expectations of exceeding $130 million by 2027, driven by higher-margin pharmaceuticals and nutraceuticals.
- U.S. Market Expansion: The report highlights Cosmos Health's entry into the U.S. market through the acquisition of ZipDoctor, a telehealth platform, and the launch of Sky Premium Life in the U.S. nutraceutical market, enhancing its competitive position.
- Advancing R&D Pipeline: Zacks notes Cosmos Health's ongoing development programs targeting obesity and multiple sclerosis, reflecting the company's strategic focus on addressing large disease markets and driving innovation in drug repurposing.
See More
